ATE435012T1 - Verfahren zur behandlung von parkinson-krankheit - Google Patents

Verfahren zur behandlung von parkinson-krankheit

Info

Publication number: ATE435012T1
Authority: AT; Austria
Prior art keywords: disease; treating parkinson; parkinson; treating
Prior art date: 2003-04-11

Application number

AT04726590T

Other languages

English (en)

Inventor

Fariello Ruggero

Carlo Cattaneo

Patricia Salvati

Luca Benatti

Original Assignee

Newron Pharm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-11

Filing date

2004-04-08

Publication date

2009-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE435012(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-08 Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa

2009-07-15 Application granted granted Critical

2009-07-15 Publication of ATE435012T1 publication Critical patent/ATE435012T1/de

Links

208000018737 Parkinson disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04726590T 2003-04-11 2004-04-08 Verfahren zur behandlung von parkinson-krankheit ATE435012T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46220503P	2003-04-11	2003-04-11
PCT/IB2004/001408 WO2004089353A2 (en)	2003-04-11	2004-04-08	Methods for treatment of parkinson's disease

Publications (1)

Publication Number	Publication Date
ATE435012T1 true ATE435012T1 (de)	2009-07-15

Family

ID=33159845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04726590T ATE435012T1 (de)	2003-04-11	2004-04-08	Verfahren zur behandlung von parkinson-krankheit

Country Status (28)

Country	Link
US (3)	US8283380B2 (de)
EP (2)	EP2070526B1 (de)
JP (2)	JP2006522800A (de)
KR (2)	KR101129015B1 (de)
CN (2)	CN1771030A (de)
AR (1)	AR044007A1 (de)
AT (1)	ATE435012T1 (de)
AU (1)	AU2004228782B2 (de)
BR (1)	BRPI0409364A (de)
CA (1)	CA2523188C (de)
CY (3)	CY1109295T1 (de)
DE (1)	DE602004021790D1 (de)
DK (2)	DK2070526T3 (de)
ES (2)	ES2454272T3 (de)
FR (1)	FR15C0054I2 (de)
HU (1)	HUS1500043I1 (de)
IL (2)	IL171331A (de)
LU (1)	LU92782I2 (de)
MX (1)	MXPA05010873A (de)
NL (1)	NL300752I2 (de)
NO (3)	NO334316B1 (de)
NZ (1)	NZ542910A (de)
PL (2)	PL1613296T3 (de)
PT (2)	PT2070526E (de)
RU (1)	RU2342929C2 (de)
SI (2)	SI1613296T1 (de)
TW (1)	TWI340640B (de)
WO (1)	WO2004089353A2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
SI1423168T1 (sl)	2001-09-03	2006-06-30	Newron Pharm Spa	Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
EP1438956A1 (de) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-Aminoamidderivate die als Antimigränemittel nützlich sind
ES2339021T3 (es) *	2003-08-25	2010-05-14	Newron Pharmaceuticals S.P.A.	Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1588704A1 (de)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamidderivate zur Behandlung des Restless-Leg-Syndroms und der Suchterkrankungen
US20080096965A1 (en) *	2004-09-10	2008-04-24	Newron Pharmaceuticals S.P.A.	(Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
US20070004639A1 (en) *	2005-07-01	2007-01-04	Bodybio, Inc.	Methods and compositions for treating Parkinson's disease
WO2007069274A2 (en) *	2005-11-09	2007-06-21	Torrent Pharmaceuticals Limited	Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
EP1963280B1 (de)	2005-12-22	2015-10-28	Newron Pharmaceuticals S.p.A.	2-phenylethylaminoderivate als calcium- und/oder natrium-kanalmodulatoren
CN101032474B (zh) *	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (de) *	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamidederivate zur Behandlung von kognitiven Störungen
US8106056B2 (en) *	2006-06-16	2012-01-31	Solvay Pharmaceuticals B.V.	Combination preparations comprising bifeprunox and a dopamine agonist
DK2474521T3 (en)	2006-06-19	2016-10-31	Newron Pharm Spa	High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus
DE102007014947B4 (de) *	2007-03-23	2010-05-27	Axxonis Pharma Ag	Stabilisierte wässrige Lösungen von Ergolinverbindungen
WO2008129043A1 (en) *	2007-04-24	2008-10-30	Boehringer Ingelheim International Gmbh	Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
DK2155663T3 (en)	2007-06-15	2018-01-22	Newron Pharm Spa	SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND / OR CALCIUM CHANNEL MODULATORS
GB2453770A (en) *	2007-10-19	2009-04-22	Reckitt Benckiser Healthcare	Oral composition comprising a cooling agent
WO2009054964A1 (en) *	2007-10-22	2009-04-30	Concert Pharmaceuticals, Inc.	Alpha-aminoamide derivatives
KR101593627B1 (ko)	2007-12-11	2016-02-11	뉴론 파마슈티칼즈 에스. 피. 에이.	고순도의 ２［４（３ 또는 ２플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법
CA2707646C (en) *	2007-12-19	2016-09-13	Newron Pharmaceuticals S.P.A.	Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
US20110027354A1 (en) *	2008-04-01	2011-02-03	Kim Hyoung-Chun	Anti-parkinsonian compounds
NZ589470A (en) *	2008-06-02	2012-08-31	Generics Uk Ltd	A process for the preparation of rasagiline and its analogues
AU2009254927B2 (en) *	2008-06-02	2014-03-13	Generics [Uk] Limited	A process for the preparation of enantiomerically pure amines
MX2010013393A (es) *	2008-06-06	2011-06-21	Pharma Two B Ltd	Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
BRPI0909894A2 (pt) *	2008-06-13	2015-07-28	Teva Pharma	"método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
WO2010010138A1 (en) *	2008-07-24	2010-01-28	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
EP2218444A3 (de) *	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Rasagilinformulierung mit verzögerter Freisetzung
US20100189791A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
EP2314569A1 (de)	2009-10-22	2011-04-27	Merck Patent GmbH	Neuartige polymorphe Formen von (S)-2-[4-(3-Fluor-benzyloxy)-benzylamino]-Propionamidmesylatsalz und Herstellungsverfahren dafür
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) *	2010-02-09	2011-08-18	Merck Serono S.A.	Safinamide in the treatment of dyskinesia
NZ602648A (en)	2010-04-27	2014-10-31	Newron Pharm Spa	Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
JP5820469B2 (ja)	2010-04-30	2015-11-24	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダンの経皮組成物
CN103476404B (zh)	2011-03-24	2017-09-29	帝国制药美国公司	包含活性剂层和活性剂转化层的透皮组合物
US20150031768A1 (en) *	2011-08-19	2015-01-29	The Trustees Of Princeton University	C-halogen bond formation
WO2013081685A1 (en)	2011-08-19	2013-06-06	The Trustees Of Princeton University	C-halogen bond formation
WO2013070526A1 (en)	2011-11-09	2013-05-16	Teikoku Pharma Usa, Inc.	Methods for the treatment of skin neoplasms
BR112015009088A2 (pt)	2012-10-22	2017-07-04	Civitas Therapeutics Inc	formulações de levodopa para alívio rápido da doença de parkinson.
AU2013338243B2 (en)	2012-11-02	2016-09-29	Teikoku Seiyaku Co., Ltd.	Propynylaminoindan transdermal compositions
US9155695B2 (en)	2013-03-14	2015-10-13	Medtronic, Inc.	Injectable ropinirole compositions and methods for making and using same
KR20160026897A (ko)	2013-06-27	2016-03-09	세다르스-신나이 메디칼 센터	신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
AU2014391721B2 (en) *	2014-04-21	2020-07-16	Merz Pharmaceuticals, Llc	Rapid relief of motor fluctuations in Parkinson's Disease
CA2963371C (en) *	2014-10-02	2020-06-02	Korea Institute Of Science And Technology	Alpha-aminoamide derivative compound and pharmaceutical composition containing the same
WO2017032874A1 (en) *	2015-08-27	2017-03-02	Prexton Therapeutics Sa	Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
KR102889062B1 (ko) *	2016-03-17	2025-11-21	더 존스 홉킨스 유니버시티	Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
ITUA20163981A1 (it)	2016-05-31	2017-12-01	Zambon Spa	Composizioni farmaceutiche comprendenti safinamide
WO2018132746A1 (en) *	2017-01-14	2018-07-19	Mischley Laurie Kathern	Method of using human excrement and secretions for early detection of parkinson's disease
CN109251155A (zh) *	2017-07-14	2019-01-22	广东东阳光药业有限公司	α-氨基酰胺衍生物及其用途
US11234961B2 (en) *	2017-08-17	2022-02-01	Zi-Qiang Gu	Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
MX2020004403A (es)	2017-11-02	2020-08-06	Zambon Spa	Composiciones farmaceuticas que comprenden safinamida.
KR102005019B1 (ko) *	2018-04-04	2019-07-31	한국과학기술연구원	뇌졸중의 예방 및 치료용 조성물
KR20220074895A (ko) *	2019-09-12	2022-06-03	어치브 라이프 사이언시즈, 인크.	필요로 하는 대상체의 중독 치료 및/또는 예방을 위한 시티신을 포함하는 조성물
LU101477B1 (en) *	2019-11-12	2021-05-14	Univ Luxembourg	An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) *	2019-11-28	2020-03-31	岳千奥	取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
JP2023504876A (ja) *	2019-12-06	2023-02-07	シャンハイファーマシューティカルズホールディングカンパニー，リミティド	薬物組成物、キット及びその応用
CN110999980A (zh) *	2019-12-19	2020-04-14	新疆石河子职业技术学院（石河子市技工学校）	一种葡萄酒洗浸奶酪加工方法
US20230181508A1 (en) *	2020-08-31	2023-06-15	Purdue Pharma L.P.	Compositions and methods for levodopa delivery
WO2022192173A1 (en) *	2021-03-08	2022-09-15	Prothena Biosciences Limited	Treatment of parkinson's disease
KR102790040B1 (ko) *	2021-06-24	2025-04-01	연세대학교 산학협력단	도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1140748A (en)	1966-06-23	1969-01-22	Ici Ltd	New carboxylic acid derivatives
US3795739A (en) *	1972-02-14	1974-03-05	Hoffmann La Roche	Treatment of parkinson disease
US4049663A (en)	1972-06-06	1977-09-20	Allen & Hanburys Limited	Ethylene diamine derivatives
FR2480747A1 (fr)	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
US4935429A (en)	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
ES2042520T3 (es) *	1986-06-10	1993-12-16	Chiesi Farma Spa	Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
CA1336169C (en)	1988-03-01	1995-07-04	Walther Birkmayer	Agent for treatment of parkinson's disease
IL94466A (en)	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) *	1990-05-07	1993-06-22	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en)	1990-12-27	1996-03-26	Relin; Arkadi	Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en)	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ES2211904T3 (es) *	1995-05-26	2004-07-16	Pfizer Inc.	Combinaciones para el tratamiento del parkinsonismo que contienen antagonistas selectivos de nmda.
GB9515412D0 (en) *	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
US20020019421A1 (en) *	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
DE10041479A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) *	2001-08-29	2003-03-07	Aventis Pharma Sa	Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

2004
- 2004-04-07 AR ARP040101189A patent/AR044007A1/es unknown
- 2004-04-08 TW TW093109755A patent/TWI340640B/zh not_active IP Right Cessation
- 2004-04-08 DK DK09154864.4T patent/DK2070526T3/da active
- 2004-04-08 AT AT04726590T patent/ATE435012T1/de active
- 2004-04-08 PL PL04726590T patent/PL1613296T3/pl unknown
- 2004-04-08 JP JP2006506582A patent/JP2006522800A/ja active Pending
- 2004-04-08 US US10/559,982 patent/US8283380B2/en active Active
- 2004-04-08 BR BRPI0409364-0A patent/BRPI0409364A/pt not_active Application Discontinuation
- 2004-04-08 EP EP09154864.4A patent/EP2070526B1/de not_active Expired - Lifetime
- 2004-04-08 CN CNA200480009655XA patent/CN1771030A/zh active Pending
- 2004-04-08 ES ES09154864.4T patent/ES2454272T3/es not_active Expired - Lifetime
- 2004-04-08 KR KR1020057019264A patent/KR101129015B1/ko not_active Expired - Lifetime
- 2004-04-08 DE DE602004021790T patent/DE602004021790D1/de not_active Expired - Lifetime
- 2004-04-08 PT PT91548644T patent/PT2070526E/pt unknown
- 2004-04-08 RU RU2005131422/15A patent/RU2342929C2/ru active
- 2004-04-08 CA CA2523188A patent/CA2523188C/en not_active Expired - Lifetime
- 2004-04-08 PT PT04726590T patent/PT1613296E/pt unknown
- 2004-04-08 NZ NZ542910A patent/NZ542910A/en not_active IP Right Cessation
- 2004-04-08 AU AU2004228782A patent/AU2004228782B2/en not_active Expired
- 2004-04-08 SI SI200431192T patent/SI1613296T1/sl unknown
- 2004-04-08 WO PCT/IB2004/001408 patent/WO2004089353A2/en not_active Ceased
- 2004-04-08 MX MXPA05010873A patent/MXPA05010873A/es active IP Right Grant
- 2004-04-08 CN CN201110271872.8A patent/CN102274517B/zh not_active Expired - Lifetime
- 2004-04-08 PL PL09154864T patent/PL2070526T3/pl unknown
- 2004-04-08 SI SI200432150T patent/SI2070526T1/sl unknown
- 2004-04-08 EP EP04726590A patent/EP1613296B1/de not_active Expired - Lifetime
- 2004-04-08 ES ES04726590T patent/ES2326373T3/es not_active Expired - Lifetime
- 2004-04-08 KR KR1020117013555A patent/KR20110070929A/ko not_active Ceased
- 2004-04-08 DK DK04726590T patent/DK1613296T3/da active
2005
- 2005-10-10 IL IL171331A patent/IL171331A/en active Protection Beyond IP Right Term
- 2005-10-10 NO NO20054640A patent/NO334316B1/no active Protection Beyond IP Right Term
2009
- 2009-08-12 CY CY20091100857T patent/CY1109295T1/el unknown
2011
- 2011-11-17 IL IL216403A patent/IL216403A/en active IP Right Grant
2012
- 2012-08-24 US US13/594,621 patent/US8901176B2/en not_active Expired - Lifetime
- 2012-12-14 JP JP2012273371A patent/JP2013067647A/ja active Pending
2013
- 2013-10-28 NO NO20131417A patent/NO335537B1/no unknown
2014
- 2014-04-15 CY CY20141100288T patent/CY1115286T1/el unknown
- 2014-11-04 US US14/532,925 patent/US9492410B2/en not_active Expired - Fee Related
2015
- 2015-07-01 CY CY2015025C patent/CY2015025I2/el unknown
- 2015-07-17 NL NL300752C patent/NL300752I2/nl unknown
- 2015-07-22 LU LU92782C patent/LU92782I2/xx unknown
- 2015-07-22 FR FR15C0054C patent/FR15C0054I2/fr active Active
- 2015-07-22 HU HUS1500043C patent/HUS1500043I1/hu unknown
- 2015-07-23 NO NO2015018C patent/NO2015018I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
TWI340640B (en)	2011-04-21
US9492410B2 (en)	2016-11-15
MXPA05010873A (es)	2006-03-21
NO335537B1 (no)	2014-12-22
RU2342929C2 (ru)	2009-01-10
NO2015018I1 (no)	2015-08-03
JP2013067647A (ja)	2013-04-18
TW200505423A (en)	2005-02-16
NO20054640D0 (no)	2005-10-10
BRPI0409364A (pt)	2006-04-25
KR20110070929A (ko)	2011-06-24
CY1109295T1 (el)	2014-07-02
KR20060010745A (ko)	2006-02-02
FR15C0054I1 (fr)	2015-11-09
RU2005131422A (ru)	2006-04-27
CY2015025I1 (el)	2016-04-13
CY1115286T1 (el)	2017-01-04
DE602004021790D1 (de)	2009-08-13
EP2070526A1 (de)	2009-06-17
PT1613296E (pt)	2009-07-30
WO2004089353A8 (en)	2005-09-01
JP2006522800A (ja)	2006-10-05
IL216403A (en)	2015-01-29
US20150150833A1 (en)	2015-06-04
FR15C0054I2 (fr)	2018-01-26
ES2454272T3 (es)	2014-04-10
EP2070526B1 (de)	2014-02-26
CN1771030A (zh)	2006-05-10
CN102274517A (zh)	2011-12-14
WO2004089353A2 (en)	2004-10-21
NO20054640L (no)	2005-12-09
US20070093495A1 (en)	2007-04-26
US8283380B2 (en)	2012-10-09
NZ542910A (en)	2007-10-26
PT2070526E (pt)	2014-03-31
CY2015025I2 (el)	2016-04-13
AU2004228782B2 (en)	2010-05-20
WO2004089353A3 (en)	2004-12-16
DK1613296T3 (da)	2009-10-05
NO2015018I2 (no)	2015-07-23
CA2523188A1 (en)	2004-10-21
PL2070526T3 (pl)	2014-08-29
EP1613296B1 (de)	2009-07-01
IL171331A (en)	2012-03-29
PL1613296T3 (pl)	2009-12-31
EP1613296A2 (de)	2006-01-11
HUS1500043I1 (hu)	2018-11-28
US8901176B2 (en)	2014-12-02
KR101129015B1 (ko)	2012-04-20
AU2004228782A1 (en)	2004-10-21
CA2523188C (en)	2012-09-25
SI2070526T1 (sl)	2014-05-30
ES2326373T3 (es)	2009-10-08
NO334316B1 (no)	2014-02-03
DK2070526T3 (da)	2014-03-24
CN102274517B (zh)	2018-08-31
IL216403A0 (en)	2011-12-29
US20130053368A1 (en)	2013-02-28
AR044007A1 (es)	2005-08-24
NL300752I2 (de)	2016-07-05
NO20131417L (no)	2005-12-09
SI1613296T1 (sl)	2009-10-31
LU92782I2 (fr)	2015-09-22

Legal Events

Date

Code

Title

Description

2010-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1613296

Country of ref document: EP

2011-01-15

UEP